Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?

Por Roozendaal, C, Kallenberg, C G M
Publicado em 1999

Stromal influences on breast cancer cell growth.

Por van Roozendaal, C. E., van Ooijen, B., Klijn, J. G., Claassen, C., Eggermont, A. M., Henzen-Logmans, S. C., Foekens, J. A.
Publicado em 1992

Catalase and α-enolase: two novel granulocyte autoantigens in inflammatory bowel disease (IBD)

Por Roozendaal, C, Zhao, M H, Horst, G, Lockwood, C M, Kleibeuker, J H, Limburg, P C, Nelis, G F, Kallenberg, C G M
Publicado em 1998

Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands

Por van Zanten, A, Arends, S, Roozendaal, C, Limburg, P C, Maas, F, Trouw, L A, Toes, R E M, Huizinga, T W J, Bootsma, H, Brouwer, E
Publicado no Ann Rheum Dis (2017)

Efficiency of BRCAPRO and Myriad II mutation probability thresholds versus cancer history criteria alone for BRCA1/2 mutation detection

Por van Harssel, J. J. T., van Roozendaal, C. E. P., Detisch, Y., Brandão, R. D., Paulussen, A. D. C., Zeegers, M., Blok, M. J., Gómez García, E. B.
Publicado em 2009

Differential effects of donor‐specific HLA antibodies in living versus deceased donor transplant

Por Kamburova, E. G., Wisse, B. W., Joosten, I., Allebes, W. A., van der Meer, A., Hilbrands, L. B., Baas, M. C., Spierings, E., Hack, C. E., van Reekum, F. E., van Zuilen, A. D., Verhaar, M. C., Bots, M. L., Drop, A. C. A. D., Plaisier, L., Seelen, M. A. J., Sanders, J. S .F., Hepkema, B. G., Lambeck, A. J. A., Bungener, L. B., Roozendaal, C., Tilanus, M. G. J., Voorter, C. E., Wieten, L., van Duijnhoven, E. M., Gelens, M., Christiaans, M. H. L., van Ittersum, F. J., Nurmohamed, S. A., Lardy, N. M., Swelsen, W., van der Pant, K. A., van der Weerd, N. C., ten Berge, I. J. M., Bemelman, F. J., Hoitsma, A., van der Boog, P. J. M., de Fijter, J. W., Betjes, M. G. H., Heidt, S., Roelen, D. L., Claas, F. H., Otten, H. G.
Publicado no Am J Transplant (2018)

Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2

Por Osorio, A, Milne, R L, Alonso, R, Pita, G, Peterlongo, P, Teulé, A, Nathanson, K L, Domchek, S M, Rebbeck, T, Lasa, A, Konstantopoulou, I, Hogervorst, F B, Verhoef, S, van Dooren, M F, Jager, A, Ausems, M G E M, Aalfs, C M, van Asperen, C J, Vreeswijk, M, Waisfisz, Q, Van Roozendaal, C E, Ligtenberg, M J, Easton, D F, Peock, S, Cook, M, Oliver, C T, Frost, D, Curzon, B, Evans, D G, Lalloo, F, Eeles, R, Izatt, L, Davidson, R, Adlard, J, Eccles, D, Ong, K-r, Douglas, F, Downing, S, Brewer, C, Walker, L, Nevanlinna, H, Aittomäki, K, Couch, F J, Fredericksen, Z, Lindor, N M, Godwin, A, Isaacs, C, Caligo, M A, Loman, N, Jernström, H, Barbany-Bustinza, G, Liljegren, A, Ehrencrona, H, Stenmark-Askmalm, M, Feliubadaló, L, Manoukian, S, Peissel, B, Zaffaroni, D, Bonanni, B, Fortuzzi, S, Johannsson, O T, Chenevix-Trench, G, Chen, X-C, Beesley, J, Spurdle, A B, Sinilnikova, O M, Healey, S, McGuffog, L, Antoniou, A C, Brunet, J, Radice, P, Benítez, J
Publicado em 2011